TGFBR1 and neoplasm: In this study, we found that both highly recurrent (CHEK2 K373E) and rare point mutations (CHEK2 S372F/Y and A392V, TGFBR1 S241L and L354P) in tumor suppressors can also cause loss- or reduction-of-function.